Project Grant R01AG098926
Award Date 9/15/26
Completion Date 5/31/31
Dollars Obligated $459K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded the University of Florida $422,125 on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how pathological tau protein affects RNA translation and neuronal function in tauopathies, including progressive supranuclear palsy and Alzheimer's disease. The research will identify RNA transcripts that bind to tau in primary tauopathies, characterize newly translated proteins in the presence of pathological tau, and examine tau-RNA...
- The National Institute on Aging awarded $780,217 to the University of Connecticut Health Center on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal imaging of prefrontal cholinergic dynamics and cognitive flexibility in an Alzheimer's disease model. The research combines chronic two-photon imaging, fluorescent acetylcholine reporting, in vivo beta-amyloid labeling, and cell-type-specific chemogenetic and optogenetic control to test whether amyloid-beta...
- The National Institute on Aging awarded $152,600 to Baylor College of Medicine on December 26, 2026, under the Aging Research program (CFDA 93.866) to investigate the synergistic mechanisms of tau and amyloid-beta aggregation in Alzheimer's disease pathology. The project, titled "Synergy in Condensation: Tau and AB in Alzheimer's Disease," employs advanced biophysical techniques including fluorescence lifetime imaging microscopy and microfluidic modulation infrared spectroscopy to...
- The National Institute on Aging awarded Ohio University $567,256 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the mechanisms of activity-dependent tau release in Alzheimer's disease pathogenesis. The research elucidates how neuronal hyperexcitability drives tau release from neurons and synapses, using a Drosophila model and human neural cell lines. Aim 1 investigates activity-dependent tau release from neurons and synapses, focusing on synaptic vesicle...
- The National Institute on Aging awarded The University of Texas Southwestern Medical Center $456,500 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of heparan sulfate proteoglycans in tau uptake in cell and mouse models as a potential treatment pathway for Alzheimer's disease. The research addresses gaps in understanding how heparan sulfate proteoglycans drive tau uptake in neurons and microglia, which are the brain cell types most affected in...
- The National Institute on Aging awarded Yale University $507,741 under the Aging Research program (CFDA 93.866) on August 1, 2026, to define the spatial relationship between early endosomal abnormalities, amyloid pathology, and early-stage tau hyperphosphorylation in primate models of sporadic Alzheimer's disease. The project addresses a gap in understanding the earliest molecular convergence points in Alzheimer's pathology. While soluble phosphorylated tau at threonine 217 (pT217tau) and...
- The National Institute on Aging awarded the University of Texas Medical Branch at Galveston $617,349 on June 15, 2026, under the Aging Research program (CFDA 93.866) to investigate EPAC1 signaling as a mechanism of retinal neurodegeneration during tauopathy. The research examines how activation of the cAMP/EPAC1 pathway promotes retinal neuronal injury by inducing mitochondrial dysfunction, promoting tau sumoylation and phosphorylation, and reducing clearance of tau aggregates and damaged...
- The National Institute on Aging awarded The Regents of the University of California, San Francisco $663,237 on September 1, 2026, under the Aging Research program (CFDA 93.866) to support multiscale structural approaches defining tau filaments and cellular dysfunction associated with Alzheimer's disease and related dementias (ADRDs). The research integrates histological and structural imaging methods with cryo-electron microscopy to characterize tau fibril structures, aggregate morphologies, and...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of Texas Medical Branch at Galveston $3.267 million on June 1, 2026, under the Aging Research program (CFDA 93.866). The research investigates the apolipoprotein E (APOE)-tau axis linking preeclampsia to Alzheimer's disease and related neurodegeneration. The project employs primary human trophoblast assays, pre-clinical humanized preeclampsia mouse models, and predictive and therapeutic...